Production (Stage)
Trinity Biotech plc
TRIB
$0.6341
-$0.0374-5.57%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 15.86M | 15.84M | 13.43M | 14.68M | 15.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.86M | 15.84M | 13.43M | 14.68M | 15.70M |
| Cost of Revenue | 10.98M | 10.11M | 8.86M | 10.40M | 15.38M |
| Gross Profit | 4.88M | 5.73M | 4.57M | 4.28M | 329.00K |
| SG&A Expenses | 8.37M | 6.42M | 6.94M | 7.68M | 5.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.83M | -13.00K | 0.00 | -70.00K | -1.00K |
| Total Operating Expenses | 22.63M | 17.51M | 16.91M | 19.18M | 21.55M |
| Operating Income | -6.78M | -1.67M | -3.49M | -4.50M | -5.84M |
| Income Before Tax | -15.80M | -6.89M | -5.50M | -6.50M | -9.99M |
| Income Tax Expenses | 585.00K | -131.00K | -3.00K | 222.00K | 2.00K |
| Earnings from Continuing Operations | -16.38M | -6.76M | -5.50M | -6.72M | -9.99M |
| Earnings from Discontinued Operations | -573.00K | -- | -3.00K | -1.00K | 1.04M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.96M | -6.76M | -5.50M | -6.72M | -8.95M |
| EBIT | -6.78M | -1.67M | -3.49M | -4.50M | -5.84M |
| EBITDA | -6.35M | -1.51M | -3.03M | -4.27M | -5.10M |
| EPS Basic | -25.57 | -14.28 | -14.35 | -17.54 | -23.47 |
| Normalized Basic EPS | -0.61 | -0.30 | -- | -- | -- |
| EPS Diluted | -25.60 | -14.28 | -14.35 | -17.54 | -23.60 |
| Normalized Diluted EPS | -0.61 | -0.30 | -- | -- | -- |
| Average Basic Shares Outstanding | 13.26M | 9.47M | 7.66M | 7.67M | 7.62M |
| Average Diluted Shares Outstanding | 662.90K | 473.20K | 382.70K | 383.20K | 381.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |